

Edgar Filing: EXELIXIS INC - Form 8-K

EXELIXIS INC  
Form 8-K  
January 11, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 28, 2001

EXELIXIS, INC. (Exact name of registrant as specified in its charter)

DELAWARE

0-30235

04-3257395

(State or other jurisdiction of incorporation) (Commission File No.) (I.R.S. Employer Identification No.)

170 Harbor Way  
P.O. Box 511  
South San Francisco, CA 94083  
(Address of principal executive offices, including zip code)  
(650) 837-7000  
(Registrant's telephone number, including area code)

Item 2. Acquisition or Disposition of Assets.

On December 28, 2001, Bluegreen Acquisition Sub, Inc. ("MERGER SUB"), a wholly owned subsidiary of Exelixis, Inc. ("EXELIXIS"), accepted for payment approximately 22,911,969 shares of common stock, or approximately 93.94% of the total number of outstanding shares of common stock of Genomica Corporation ("GENOMICA"). These shares were validly tendered pursuant to Merger Sub's exchange offer (the "OFFER") for all of the outstanding shares of Genomica at an exchange ratio of 0.28309 of a share of Exelixis common stock for each share of Genomica common stock. The Offer expired at 12:00 midnight, New York City time, on Friday, December 28, 2001.

On January 8, 2002, the merger of Genomica and Merger Sub (the "MERGER") was consummated. Upon the effectiveness of the Merger, Genomica became a wholly owned subsidiary of Exelixis. A total of approximately 6,904,452 shares of Exelixis common stock will be issued for all of the outstanding shares of Genomica common stock.

Item 7. Financial Statements and Exhibits.

(a) The financial statements required by Item 7(a) previously were filed as part of the Registrant's registration statement on Form S-4, as amended (Registration No. 333-74120).

Edgar Filing: EXELIXIS INC - Form 8-K

(b) The pro forma financial information required by Item 7(b) previously was filed as part of the Registrant's registration statement on Form S-4, as amended (Registration No. 333-74120).

(c) The Agreement and Plan of Merger and Reorganization, dated as of November 19, 2001, by and among the Registrant, Bluegreen Acquisition Sub, Inc. and Genomica Corporation, previously was filed as an annex to the Registrant's registration statement on Form S-4, as amended (Registration No. 333-74120).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: January 11, 2002

Exelixis, Inc.

/s/ George A. Scangos

-----  
George A. Scangos  
President and Chief Executive Officer

=====